Sunday , November 17 2019
Home / zimbabwe / LAM on & # 39; presents new data that show a high diagnostic potential of DNA methylation acellular Assay Fo (9)

LAM on & # 39; presents new data that show a high diagnostic potential of DNA methylation acellular Assay Fo (9)


Irvine, California.. March 31, 2019 / PRNewswire / – Advanced Laboratory Medicine (LAM), the commercial stage medical technology company focused on developing innovative technologies for the early detection of cancer, today announced new data at the American Association for Cancer Research (AACR) Annual Meeting at the Georgia World Congress Center in Atlanta, GAObtained data indicate patented IvyGene Lam Tests have the ability to detect liver cancer, with 95% sensitivity and 97.5% specificity, breast cancer, with 89% sensitivity and 96% specificity and colorectal cancer with 93% sensitivity and 100% specificity.

"Early detection of cancer & # 39 is a key advantage for successful treatment," said Dr. Shu LiChairman Lam. "The classical methods of screening & # 39 are invasive, expensive and time consuming, while our tests require only a simple blood test. For this simple sophisticated technology developed over many years of research on the LAM. Early detection of unmet medical need, and we believe that the potential benefits to society could be huge. "

Three tests were blinded study conducted to evaluate the individual panels of DNA methylation markers developed to detect liver, breast or colorectal cancer. Determining the amount of DNA methylation in the target sites of cancer specific markers were able to differentiate high sub & # 39; objects with the diagnosis sensitivity and specificity of cancer from healthy donors and patients with benign diseases.

The results show the high diagnostic potential methylation markers cfDNA isolated from the blood for the determination of several types of cancer in different stages. In addition, quantitative analysis of the methylation signatures cfDNA provides an opportunity for monitoring the disease. Advantages of a sensitive and specific assay for the detection of cancer and the monitor is expected to help manage disease and ultimately improve patient outcomes.

For more information, please see the abstract here.

About Laboratory Medicine perspective

LAM with a & # 39 is a commercial stage medical technology company focused on developing innovative, non-invasive, non-toxic technology for the early diagnosis of cancer, and interventions. The company specializes in building and growing a world-class technologies from the laboratory to the clinic.

It located in USA with offices in California. Texas and Indiana, The LAM has collaboration with leading scientists, physicians, research institutes and business leaders in the US and ChinaWho combines his experience to provide the most effective and safe diagnostic technologies for patients and their doctors. The company has the OPC register and CAP-accredited, as well as other laboratories and cGMP on the & # 39 facilities all work towards bringing the medical community first-class technology today.

See original content to load media: HTTP: // early, non-invasive detection of-the liver, breast and colorectal-cancer-on-AACR-2019-300821295.html-

SOURCE Advanced Laboratory Medicine (LAM)

Source link